- Home
- HRMY vs WGS Comparison
HRMY vs WGS Comparison
Compare HRMY & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRMY | WGS |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.4B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | HRMY | WGS |
|---|---|---|
| Price | $35.24 | $165.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $50.56 | ★ $130.63 |
| AVG Volume (30 Days) | ★ 934.4K | 514.5K |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.44 | N/A |
| EPS | ★ 3.17 | 0.07 |
| Revenue | ★ $825,944,000.00 | $402,190,000.00 |
| Revenue This Year | $20.68 | $39.54 |
| Revenue Next Year | $15.93 | $22.50 |
| P/E Ratio | ★ $11.14 | $2,270.22 |
| Revenue Growth | 21.13 | ★ 50.50 |
| 52 Week Low | $25.52 | $55.17 |
| 52 Week High | $40.93 | $170.75 |
Technical Indicators
Market Signals| Indicator | HRMY | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 71.09 | 73.47 |
| Support Level | $32.77 | $119.43 |
| Resistance Level | $36.20 | $170.75 |
| Average True Range (ATR) | 1.11 | 9.18 |
| MACD | 0.17 | 3.28 |
| Stochastic Oscillator | 81.04 | 90.10 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.